vs
爱利金融（EFSI）与STANDARD BIOTOOLS INC.（LAB）财务数据对比。点击上方公司名可切换其他公司
STANDARD BIOTOOLS INC.的季度营收约是爱利金融的1.2倍（$19.6M vs $16.4M），爱利金融同比增速更快（21.3% vs -11.5%），爱利金融自由现金流更多（$24.3M vs $-23.1M），过去两年爱利金融的营收复合增速更高（1.5% vs -12.2%）
爱利金融公司是一家注册于特拉华州的美国银行控股公司，总部位于密歇根州底特律市的爱利底特律中心。该公司提供多种金融服务，涵盖汽车金融、直营银行线上银行服务、企业贷款、车辆保险、按揭贷款，以及分期销售、租赁协议等相关融资服务。
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
EFSI vs LAB — 直观对比
营收规模更大
LAB
是对方的1.2倍
$16.4M
营收增速更快
EFSI
高出32.8%
-11.5%
自由现金流更多
EFSI
多$47.4M
$-23.1M
两年增速更快
EFSI
近两年复合增速
-12.2%
损益表 — Q4 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $16.4M | $19.6M |
| 净利润 | — | $-34.7M |
| 毛利率 | — | 48.5% |
| 营业利润率 | 33.6% | -168.5% |
| 净利率 | — | -177.4% |
| 营收同比 | 21.3% | -11.5% |
| 净利润同比 | — | -28.8% |
| 每股收益（稀释后） | $1.10 | $-0.09 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EFSILAB
| Q4 25 | $16.4M | — | ||
| Q3 25 | $22.4M | $19.6M | ||
| Q2 25 | $20.6M | $21.8M | ||
| Q1 25 | $4.8M | $40.8M | ||
| Q4 24 | $22.0M | — | ||
| Q3 24 | $18.4M | $22.1M | ||
| Q2 24 | $16.5M | $22.5M | ||
| Q1 24 | $15.9M | $45.5M |
净利润EFSILAB
| Q4 25 | — | — | ||
| Q3 25 | $5.6M | $-34.7M | ||
| Q2 25 | $5.3M | $-33.5M | ||
| Q1 25 | $-7.0M | $-26.0M | ||
| Q4 24 | — | — | ||
| Q3 24 | $3.4M | $-26.9M | ||
| Q2 24 | $3.2M | $-45.7M | ||
| Q1 24 | $2.5M | $-32.2M |
毛利率EFSILAB
| Q4 25 | — | — | ||
| Q3 25 | — | 48.5% | ||
| Q2 25 | — | 48.8% | ||
| Q1 25 | — | 48.4% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 54.9% | ||
| Q2 24 | — | 46.1% | ||
| Q1 24 | — | 53.1% |
营业利润率EFSILAB
| Q4 25 | 33.6% | — | ||
| Q3 25 | 30.9% | -168.5% | ||
| Q2 25 | 31.8% | -118.1% | ||
| Q1 25 | -189.0% | -80.8% | ||
| Q4 24 | 36.8% | — | ||
| Q3 24 | 21.6% | -120.9% | ||
| Q2 24 | 22.9% | -134.5% | ||
| Q1 24 | 19.1% | -132.2% |
净利率EFSILAB
| Q4 25 | — | — | ||
| Q3 25 | 25.0% | -177.4% | ||
| Q2 25 | 25.6% | -153.7% | ||
| Q1 25 | -145.8% | -63.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | 18.6% | -122.0% | ||
| Q2 24 | 19.3% | -203.3% | ||
| Q1 24 | 16.0% | -70.6% |
每股收益（稀释后）EFSILAB
| Q4 25 | $1.10 | — | ||
| Q3 25 | $1.04 | $-0.09 | ||
| Q2 25 | $0.98 | $-0.09 | ||
| Q1 25 | $-1.53 | $-0.07 | ||
| Q4 24 | $1.74 | — | ||
| Q3 24 | $0.97 | $-0.07 | ||
| Q2 24 | $0.89 | $-0.12 | ||
| Q1 24 | $0.72 | $-0.27 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $129.4M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $188.8M | $399.7M |
| 总资产 | $1.9B | $539.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EFSILAB
| Q4 25 | — | — | ||
| Q3 25 | — | $129.4M | ||
| Q2 25 | — | $158.6M | ||
| Q1 25 | — | $150.9M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $210.6M | ||
| Q2 24 | — | $269.8M | ||
| Q1 24 | — | $287.1M |
总债务EFSILAB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $55.2M | ||
| Q2 24 | — | $55.1M | ||
| Q1 24 | — | $55.0M |
股东权益EFSILAB
| Q4 25 | $188.8M | — | ||
| Q3 25 | $185.6M | $399.7M | ||
| Q2 25 | $179.6M | $424.5M | ||
| Q1 25 | $176.5M | $454.6M | ||
| Q4 24 | $119.0M | — | ||
| Q3 24 | $117.8M | $489.3M | ||
| Q2 24 | $111.1M | $510.3M | ||
| Q1 24 | $107.7M | $577.3M |
总资产EFSILAB
| Q4 25 | $1.9B | — | ||
| Q3 25 | $1.9B | $539.6M | ||
| Q2 25 | $2.0B | $557.0M | ||
| Q1 25 | $1.9B | $579.6M | ||
| Q4 24 | $1.9B | — | ||
| Q3 24 | $1.9B | $681.5M | ||
| Q2 24 | $1.8B | $708.7M | ||
| Q1 24 | $1.8B | $777.7M |
负债/权益比EFSILAB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.11× | ||
| Q2 24 | — | 0.11× | ||
| Q1 24 | — | 0.10× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $25.8M | $-22.2M |
| 自由现金流经营现金流 - 资本支出 | $24.3M | $-23.1M |
| 自由现金流率自由现金流/营收 | 148.6% | -118.1% |
| 资本支出强度资本支出/营收 | 8.6% | 4.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $39.7M | $-111.1M |
8季度趋势，按日历期对齐
经营现金流EFSILAB
| Q4 25 | $25.8M | — | ||
| Q3 25 | $8.2M | $-22.2M | ||
| Q2 25 | $2.6M | $-20.7M | ||
| Q1 25 | $5.8M | $-30.3M | ||
| Q4 24 | $18.8M | — | ||
| Q3 24 | $7.5M | $-27.9M | ||
| Q2 24 | $-1.8M | $-39.0M | ||
| Q1 24 | $6.8M | $-62.5M |
自由现金流EFSILAB
| Q4 25 | $24.3M | — | ||
| Q3 25 | $7.8M | $-23.1M | ||
| Q2 25 | $2.3M | $-22.6M | ||
| Q1 25 | $5.3M | $-35.3M | ||
| Q4 24 | $17.7M | — | ||
| Q3 24 | $7.3M | $-30.1M | ||
| Q2 24 | $-2.2M | $-41.0M | ||
| Q1 24 | $6.7M | $-63.3M |
自由现金流率EFSILAB
| Q4 25 | 148.6% | — | ||
| Q3 25 | 35.0% | -118.1% | ||
| Q2 25 | 11.2% | -103.6% | ||
| Q1 25 | 110.1% | -86.6% | ||
| Q4 24 | 80.6% | — | ||
| Q3 24 | 39.6% | -136.4% | ||
| Q2 24 | -13.6% | -182.2% | ||
| Q1 24 | 41.9% | -138.9% |
资本支出强度EFSILAB
| Q4 25 | 8.6% | — | ||
| Q3 25 | 1.7% | 4.5% | ||
| Q2 25 | 1.3% | 8.7% | ||
| Q1 25 | 11.2% | 12.4% | ||
| Q4 24 | 4.6% | — | ||
| Q3 24 | 1.3% | 10.2% | ||
| Q2 24 | 2.6% | 8.6% | ||
| Q1 24 | 0.6% | 1.7% |
现金转化率EFSILAB
| Q4 25 | — | — | ||
| Q3 25 | 1.47× | — | ||
| Q2 25 | 0.49× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.19× | — | ||
| Q2 24 | -0.57× | — | ||
| Q1 24 | 2.65× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EFSI
| Asset Management | $6.0M | 37% |
| Other | $3.8M | 23% |
| Interchange Fees | $3.5M | 22% |
| Overdrawn Account Fees | $1.6M | 10% |
| Brokerage Commissions | $1.4M | 9% |
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |
